As the use of anti-angiogenic treatments is gaining scope in the treatment of various malignancies, there are increasing reports of laryngeal side effects. We report two cases of laryngeal necrosis and dysphonia.
Two patients with gynecological malignancies presented with severe dysphonia 11-24 months after initiation of bevacizumab therapy. Videostroboscopic examination of the larynx revealed bilateral ulcerations and eschar of the superior surface with absent mucosal waves.
Patients were treated with discontinuation of the bevacizumab, vocal rest, and proton pump inhibitors. Both had improvement in voice and resolution of the eschar and ulceration. Shallow sulci and mild breathiness persisted in one patient.
With increasing use of potent systemic anti-angiogenic compounds, clinicians should be vigilant of this important complication of therapy. Time to onset of symptoms and reversibility of symptoms vary by patient and require further study. There may be long-term voice sequelae.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Voice
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation.Int Arch Allergy Immunol. 1995; 107: 233-235https://doi.org/10.1159/000236988
- Bevacizumab.Oncologist. 2010; 15: 819-825https://doi.org/10.1634/theoncologist.2009-0317
- Hoarseness after metastatic colon cancer treatment.JAMA Otolaryngol Head Neck Surg. 2014; 140: 881-882https://doi.org/10.1001/jamaoto.2014.1766
- Bevacizumab-induced laryngeal necrosis.Ann Oncol. 2011; 23: 276-278https://doi.org/10.1093/annonc/mdr515
- Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.Am J Physiol Heart Circ Physiol. 2006; 290: H547-H559https://doi.org/10.1152/ajpheart.00616.2005
- Bevacizumab-induced dysphonia: a case report with a brief review of literature.J Oncol Pharm Pract. 2020; 26: 1032-1036https://doi.org/10.1177/1078155219889388
Published online: December 21, 2020
Accepted: November 25, 2020
© 2020 The Voice Foundation. Published by Elsevier Inc. All rights reserved.